T helper cells in synovial fluid of patients with rheumatoid arthritis primarily have a Th1 and a CXCR3+Th2 phenotype

Autor: Jonathan Aldridge, Anna-Karin H. Ekwall, Linda Mark, Beatrice Bergström, Kerstin Andersson, Inger Gjertsson, Anna-Carin Lundell, Anna Rudin

Publikováno v: Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)

Abstract Background The majority of CD4+ T helper (Th) cells found in the synovial fluid (SF) of patients with rheumatoid arthritis (RA) express CXCR3, a receptor associated with Th1 cells. In blood, subsets of Th2 and Th17 cells also express CXCR3,

Externí odkaz: https://doaj.org/article/e867ba4571aa41aeb005564714fcce56

The Rheumatoid Arthritis Risk Gene AIRE Is Induced by Cytokines in Fibroblast-Like Synoviocytes and Augments the Pro-inflammatory Response

Autor: Beatrice Bergström, Christina Lundqvist, Georgios K. Vasileiadis, Hans Carlsten, Olov Ekwall, Anna-Karin H. Ekwall

Publikováno v: Frontiers in Immunology, Vol 10 (2019)

The autoimmune regulator AIRE controls the negative selection of self-reactive T-cells as well as the induction of regulatory T-cells in the thymus by mastering the transcription and presentation of tissue restricted antigens (TRAs) in thymic cells.

Externí odkaz: https://doaj.org/article/c9a26656dd2145d49002ad8f61e4601b

POS0677 CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS

Autor: A. Rubbert-Roth, B. Combe, Z. Szekanecz, S. Hall, B. Haraoui, S. Attar, A. K. H. Ekwall, Y. Song, T. Shaw, O. Nagy, R. Xavier

Publikováno v: Annals of the Rheumatic Diseases. 81:613-614

BackgroundUpadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1–4ObjectivesThis post hoc analysis aimed to evaluate the consistency in time to achieving meani

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7ea0e2c8b7f2b8f41ee057293a45761
https://doi.org/10.1136/annrheumdis-2022-eular.1591

POS0562 AUTOANTIBODIES TO JOINT PROTEINS AS NOVEL BIOMARKERS FOR THE DIAGNOSIS OF UNTREATED EARLY RHEUMATOID ARTHRITIS

Autor: E. Lönnblom, M. Leu Agelii, O. Sareila, I. Hafström, M. Andersson, L. Cheng, G. Bergström, A. K. H. Ekwall, A. Rudin, A. Kastbom, C. Sjowall, B. Xu, L. T. H. Jacobsson, J. Viljanen, J. Kihlberg, I. Gjertsson, R. Holmdahl

Publikováno v: Annals of the Rheumatic Diseases. 81:546.1-546

BackgroundAutoantibodies to citrullinated protein (ACPA; measured as anti-CCP; aCCP) and rheumatoid factor (RF) appear years before clinical onset of RA and are essential tools in today’s classification criteria for RA. In animal models, antibodies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a14d3de4bac791f769cf40b4bb2439d
https://doi.org/10.1136/annrheumdis-2022-eular.3698

Active conventional treatment and three different biological treatments in early rheumatoid arthritis:phase IV investigator initiated, randomised, observer blinded clinical trial

Autor: Giovanni Cagnotto, Dan Nordström, Joakim Lindqvist, Lise Hyldstrup, Jon Lampa, Anna-Karin H. Ekwall, Gerdur Gröndal, Torkell Ellingsen, Tomas Husmark, Oliver Hendricks, Kim Hørslev-Petersen, Meliha C Kapetanovic, Daisy Vedder, Merete Lund Hetland, Marte Schrumpf Heiberg, Kristina Lend, Espen A Haavardsholm, David John Stevens, F. Faustini, Riitta Tuompo, Annika Soderbergh, T. Sokka-Isler, Tove Lorenzen, Per Larsson, Jos W. R. Twisk, Anna Rudin, Milad Rizk, Bjorn Gudbjornsson, Ronald F van Vollenhoven, Inge C. Olsen, M. T. Nurmohamed, Søren Andreas Just, Eli Brodin, Gunnstein Bakland, Mikkel Østergaard, Åsa Reckner Olsson, Line Uhrenholt, Kathrine Lederballe Grøn, Trine Bay Laurberg, Eva Baecklund, Simon Krabbe, Till Uhlig, Maud Kristine Aga Ljoså

Publikováno v: Hetland, M L, Haavardsholm, E A, Rudin, A, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Lampa, J, Hørslev-Petersen, K, Uhlig, T, Grondal, G, Østergaard, M, Heiberg, M S, Twisk, J, Lend, K, Krabbe, S, Hyldstrup, L H, Lindqvist, J, Hultgård Ekwall, A K, Grøn, K L, Kapetanovic, M, Faustini, F, Tuompo, R, Lorenzen, T, Cagnotto, G, Baecklund, E, Hendricks, O, Vedder, D, Sokka-Isler, T, Husmark, T, Ljoså, M K A, Brodin, E, Ellingsen, T, Söderbergh, A, Rizk, M, Olsson, Å R, Larsson, P, Uhrenholt, L, Just, S A, Stevens, D J, Laurberg, T B, Bakland, G, Olsen, I C, van Vollenhoven, R & NORD-STAR Study Group 2020, ' Active conventional treatment and three different biological treatments in early rheumatoid arthritis : phase IV investigator initiated, randomised, observer blinded clinical trial ', B M J, vol. 371, m4328 . https://doi.org/10.1136/bmj.m4328
BMJ. British Medical Journal
BMJ (Clinical research ed.), 371:m4328. British Medical Association
Hetland, M L, Haavardsholm, E A, Rudin, A, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Lampa, J, Hørslev-Petersen, K, Uhlig, T, Grondal, G, Østergaard, M, Heiberg, M S, Twisk, J, Lend, K, Krabbe, S, Hyldstrup, L H, Lindqvist, J, Hultgård Ekwall, A-K, Grøn, K L, Kapetanovic, M, Faustini, F, Tuompo, R, Lorenzen, T, Cagnotto, G, Baecklund, E, Hendricks, O, Vedder, D, Sokka-Isler, T, Husmark, T, Ljoså, M-K A, Brodin, E, Ellingsen, T, Söderbergh, A, Rizk, M, Olsson, Å R, Larsson, P, Uhrenholt, L, Just, S A, Stevens, D J, Laurberg, T B, Bakland, G, Olsen, I C, van Vollenhoven, R & NORD-STAR Study Group 2020, ' Active conventional treatment and three different biological treatments in early rheumatoid arthritis : phase IV investigator initiated, randomised, observer blinded clinical trial ', The BMJ, vol. 371, m4328 . https://doi.org/10.1136/bmj.m4328
Hetland, M L, Haavardsholm, E A, Rudin, A, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Lampa, J, Hørslev-Petersen, K, Uhlig, T, Grondal, G, Østergaard, M, Heiberg, M S, Twisk, J, Lend, K, Krabbe, S, Hyldstrup, L H, Lindqvist, J, Hultgård Ekwall, A K, Grøn, K L, Kapetanovic, M, Faustini, F, Tuompo, R, Lorenzen, T, Cagnotto, G, Baecklund, E, Hendricks, O, Vedder, D, Sokka-Isler, T, Husmark, T, Ljoså, M K A, Brodin, E, Ellingsen, T, Söderbergh, A, Rizk, M, Olsson, Å R, Larsson, P, Uhrenholt, L, Just, S A, Stevens, D J, Laurberg, T B, Bakland, G, Olsen, I C & Van Vollenhoven, R 2020, ' Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial ', The BMJ, vol. 371, m4328 . https://doi.org/10.1136/bmj.m4328
The BMJ, 371:m4328
Hetland, M L, Haavardsholm, E A, Rudin, A, Nordström, D, Nurmohamed, M, Gudbjornsson, B, Lampa, J, Hørslev-Petersen, K, Uhlig, T, Grondal, G, Østergaard, M, Heiberg, M S, Twisk, J, Lend, K, Krabbe, S, Hyldstrup, L H, Lindqvist, J, Hultgård Ekwall, A K, Grøn, K L, Kapetanovic, M, Faustini, F, Tuompo, R, Lorenzen, T, Cagnotto, G, Baecklund, E, Hendricks, O, Vedder, D, Sokka-Isler, T, Husmark, T, Ljoså, M K A, Brodin, E, Ellingsen, T, Söderbergh, A, Rizk, M, Olsson, Å R, Larsson, P, Uhrenholt, L, Just, S A, Stevens, D J, Laurberg, T B, Bakland, G, Olsen, I C, van Vollenhoven, R & NORD-STAR study group 2020, ' Active conventional treatment and three different biological treatments in early rheumatoid arthritis : phase IV investigator initiated, randomised, observer blinded clinical trial ', BMJ (Clinical research ed.), vol. 371, m4328 . https://doi.org/10.1136/bmj.m4328
The BMJ

Objective To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. Design Investigator initiated, randomised, open label

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de1e4e2266731590418a688d446355fd
https://findresearcher.sdu.dk:8443/ws/files/175132336/bmj.m4328.full.pdf